Ifinatamab deruxtecan clinical trials
Also written DS-7300a and MK-2400.
How each study uses ifinatamab deruxtecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ifinatamab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2025 (7)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 1
Merck Sharp & Dohme LLC (10) · Daiichi Sankyo (6) · Rahul Aggarwal (1)
Often tested with
Tested in the same studies.
Raludotatug deruxtecan (2) · Gocatamig (2) · 5-HT3 antagonists (1) · NK1 receptor antagonists (1) · Sacituzumab tirumotecan (1) · Vibostolimab (1) · Boserolimab (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test ifinatamab deruxtecan.
- Apr 2027Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsPhase 1/2 · Daiichi Sankyo
- Jun 2027A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)Phase 1/2 · Merck Sharp & Dohme LLC
- Jul 2027A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)Phase 1/2 · Daiichi Sankyo
Studies
Open first, then newest update. How each study uses ifinatamab deruxtecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780111Written as I-DXd
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780098Written as I-DXD
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07405151Written as I-DXd
- Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate CancerNot yet recruitingPhase 2Rahul AggarwalNCT07925268Written as Ifinatamab Deruxtecan
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07227597Written as I-DXd
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06925737Written as Ifinatamab deruxtecan
- A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07630974Written as Ifinatamab Deruxtecan
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as Ifinatamab Deruxtecan (I-DXd)
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingPhase 3Daiichi SankyoNCT06644781Written as Ifinatamab deruxtecan
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)RecruitingPhase 1/2Daiichi SankyoNCT06330064Written as Ifinatamab deruxtecan
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06863272Written as Ifinatamab Deruxtecan
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780137Written as Ifinatamab Deruxtecan (I-DXd)
- A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)RecruitingPhase 1/2Daiichi SankyoNCT06362252Written as Ifinatamab deruxtecan
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06203210Written as Ifinatamab deruxtecan
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06780085Written as Ifinatamab Deruxtecan
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsActive, not recruitingPhase 1/2Daiichi SankyoNCT04145622Written as Ifinatamab deruxtecan (I-DXd)
- Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Active, not recruitingPhase 2Daiichi SankyoNCT05280470Written as Ifinatamab Deruxtecan (I-DXd)
Given beside what is tested · 1 — ifinatamab deruxtecan is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call ifinatamab deruxtecan · ClinicalTrials.gg INT016190
- UNII (FDA) C6I0GC0GX5IFINATAMAB DERUXTECANOne source FDA
- NCI Thesaurus C171577Ifinatamab DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C6I0GC0GX5 | IFINATAMAB DERUXTECAN | One source FDA |
| NCI Thesaurus | C171577 | Ifinatamab Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.